Levocarnitine Solution
NDC Package 71656-016-50

11-digit billing NDC: 71656001650 · Billing unit: ML · 250 ML per package

Package Information

Levocarnitine (levocarnitine oral) solution is levocarnitine oral solution is indicated in the treatment of primary systemic carnitine deficiency. This formulation utilizes a solution delivery system. Marketed by Saptalis Pharmaceuticals, Llc, this product is identified by NDC 71656-016 and is authorized under FDA application ANDA212533.

Identification & Billing

NDC Package Code
71656-016-50
Package Description
50 CUP, UNIT-DOSE in 1 TRAY / 5 mL in 1 CUP, UNIT-DOSE (71656-016-05)
Product Code
11-Digit Billing Format
71656001650
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
250 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Levocarnitine
Non-Proprietary Name
Levocarnitine Oral
Substance Name
Levocarnitine
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Levocarnitine oral solution is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine oral solution is also indicated for the acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.

Regulatory & Marketing

Labeler Name
Saptalis Pharmaceuticals, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA212533
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-21-2024
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (71656-016). Click a package code to view its specific billing and regulatory data.

100 CUP, UNIT-DOSE in 1 TRAY / 5 mL in 1 CUP, UNIT-DOSE (71656-016-05)
100 CUP, UNIT-DOSE in 1 TRAY / 10 mL in 1 CUP, UNIT-DOSE (71656-016-10)
118 mL in 1 BOTTLE
50 CUP, UNIT-DOSE in 1 TRAY / 10 mL in 1 CUP, UNIT-DOSE (71656-016-10)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71656-016-50 identifies a specific commercial package of 50 cup, unit-dose in 1 tray / 5 ml in 1 cup, unit-dose (71656-016-05) of Levocarnitine, a human prescription drug labeled by Saptalis Pharmaceuticals, Llc. This product is billed per "ML" milliliter and contains an estimated amount of 250 billable units per package. This solution is formulated for oral use and contains levocarnitine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Saptalis Pharmaceuticals, Llc on February 21, 2024. The current certification is valid through December 31, 2026.

How is this Saptalis Pharmaceuticals, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71656001650. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 250 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71656-016-50
11-Digit CMS (5-4-2)
71656-0016-50

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.